Scandion Oncology A/S (SCOL) AI Stock Analysis

• Market Cap: kr3.90M
• Dividend Yield: N/A
• Average Volume (3M): 2.92M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.25
• Revenue Growth: N/A
• EPS Growth: 57.91%
• Country: SE
• Employees: 4
• Sector: Healthcare
• Sector Strength: 44
• Industry: Biotechnology
• EPS (TTM): -0.10
• Shares Outstanding: 234,761,410
• 10 Day Avg. Volume: 1,107,296
• 30 Day Avg. Volume: 2,923,358
• PEG Ratio: >-0.01
• Price to Book (P/B): 0.06
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -0.08
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 30 Underperform
• Price Target: ―

Scandion Oncology A/S faces significant financial and operational challenges typical of early-stage biotech companies. The lack of revenue and consistent losses are major concerns, compounded by reliance on external funding. Technical indicators suggest weak momentum, and the valuation is constrained by the negative P/E ratio due to ongoing losses. Overall, the stock is high-risk with uncertain prospects, primarily influenced by its financial health and market trends.

Scandion Oncology A/S Business Overview & Revenue Model

Company Description

Scandion Oncology A/S (SCOL) is a biotechnology company specializing in developing innovative treatments to overcome drug resistance in cancer therapy. The company focuses on creating and advancing pharmaceutical solutions that enhance the effectiveness of existing cancer treatments. Scandion Oncology's core product portfolio includes proprietary drug candidates designed to counteract resistance mechanisms in cancer cells, thus improving patient outcomes in oncology sectors.

How the Company Makes Money

Scandion Oncology A/S makes money through the development and commercialization of its drug candidates aimed at reversing cancer drug resistance. The company's revenue model primarily involves research and development collaborations, licensing agreements, and potential milestone payments from pharmaceutical partners. These partnerships can include upfront payments, research funding, and royalties on the sales of successfully marketed drugs. Additionally, Scandion Oncology may receive governmental or institutional grants to support their innovative research efforts. As the company's drug candidates progress through clinical trials and achieve regulatory approvals, these financial streams become crucial in driving growth and sustaining operations.

Scandion Oncology A/S Financial Statement Overview

Summary

Income Statement

Balance Sheet

Cash Flow

Breakdown
TTM	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement		Total Revenue
0.00	0.00	0.00	0.00	0.00	205.44K
	Gross Profit
0.00	0.00	0.00	0.00	0.00	-11.16M
	EBIT
-38.31M	-45.36M	-80.17M	-55.37M	-22.89M	-15.39M
	EBITDA
-37.46M	-45.53M	-80.82M	-56.10M	-22.85M	-15.60M
	Net Income Common Stockholders
-32.47M	-39.20M	-76.70M	-51.70M	-16.27M	-12.18M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
26.52M	26.52M	77.61M	105.71M	5.81M	15.42M
	Total Assets
34.56M	34.56M	89.40M	116.22M	186.41M	19.90M
	Total Debt
499.00K	499.00K	1.60M	1.22M	316.00K	1.42K
	Net Debt
-26.02M	-26.02M	-76.01M	-104.49M	-5.50M	-15.42M
	Total Liabilities
3.44M	3.44M	19.07M	11.68M	30.54M	1.56M
	Stockholders Equity
31.12M	31.12M	70.33M	104.54M	155.87M	18.34M
Cash Flow		Free Cash Flow
-35.72M	-50.67M	-69.86M	-50.12M	-17.50M	-10.20M
	Operating Cash Flow
-35.72M	-50.67M	-69.44M	-49.80M	-17.45M	-9.96M
	Investing Cash Flow
510.00K	288.00K	-389.00K	-485.00K	-46.00K	-238.28K
	Financing Cash Flow
13.69M	-705.00K	41.73M	150.18M	7.89M	17.95M

Scandion Oncology A/S Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.02
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:SCOL, the sentiment is Negative. The current price of 0.02 is above the 20-day moving average (MA) of 0.02, above the 50-day MA of 0.01, and below the 200-day MA of 0.07, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 42.05 is Neutral, neither overbought nor oversold. The STOCH value of 30.56 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:SCOL.

Scandion Oncology A/S Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	54 Neutral	$5.38B	3.40	-45.06%	3.28%	16.75%	-0.02%
COMBI	52 Neutral	kr47.32M	―	-47.01%	―	-94.12%	-25.83%
XINT	43 Neutral	€328.90M	―		―	5303.85%	55.59%
SPRINT	39 Underperform	€47.48M	―	-147.64%	―	30.02%	-3985.71%
LIDDS	37 Underperform	kr5.46M	―	-107.11%	―	―	94.98%
SCOL	30 Underperform	kr3.90M	―	-186.04%	―	―	57.91%